[Treatment of patients with destructive pulmonary tuberculosis and nonspecific purulent endobronchitis].
Imozymase treatment should be started from the first hospital days in patients with destructive pulmonary tuberculosis concurrent with nonspecific purulent endobronchitis. Two-week ultrasound inhalations with imozymase in a dose of 1 ml (60 PU) may rapidly abolish not only the nonspecific inflammatory bronchial process, but also accelerate the attenuation of symptoms of intoxication, the time of abacillation, cavernous closure, and preparation for surgical interventions.
Pletnev
G V
GV
Krasnov
V A
VA
Potashova
V A
VA
D000280:Administration, Inhalation; D001412:Bacillus subtilis / Q000737:chemistry; D001991:Bronchitis / Q000150:complications*; D003131:Combined Modality Therapy; D010450:Endopeptidases / Q000737:chemistry / Q000627:therapeutic use*; D004800:Enzymes, Immobilized / Q000627:therapeutic use; D006801:Humans; D013492:Suppuration; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy* / Q000601:surgery; D014464:Ultrasonic Therapy
D004800:Enzymes, Immobilized; D010450:Endopeptidases